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Abstract
Pulmonary vascular disorders including portopulmonary 
hypertension (PoPHT) are among the common 
complications of liver disease and are prognostically 
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significant. Survival is very low without medical 
treatment and liver transplantation. With advances in 
medical therapy for elevated pulmonary artery pressure 
(PAP) and liver transplant surgery, survival of patients 
with PoPHT and advanced liver disease is significantly 
improved. Because of the prognostic significance of 
PoPHT and the limited donor pool, a comprehensive 
preoperative cardio-pulmonary assessment is of great 
importance in cirrhotic patients prior to transplant 
surgery. Therefore, a detailed transthoracic Doppler 
echocardiographic examination must be an essential 
component of this evaluation. Patients with mild PoPHT 
can safely undergo liver transplant surgery. In cases of 
moderate to severe PoPHT, right heart catheterization 
(RHC) should be performed. In patients with moderate 
to severe PoPHT on RHC (mean PAP 35-45 mmHg), 
vasodilator therapy should be attempted. Liver 
transplantation should be encouraged in cases that 
demonstrate a positive response. Bridging therapy with 
specific pulmonary arterial hypertension treatment 
agents should be considered until the transplant 
surgery and should be continued during the peri- and 
post-operative periods as needed. 
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Core tip: Portopulmonary hypertension (PoPHT) is 
one of the most common findings on preoperative 
assessment of cirrhotic patients prior to liver transplant 
surgery. Since it has prognostic significance, diagnosis 
of PoPHT by Doppler echocardiography and further 
characterization by right heart catheterization is critical 
in classifying these patients. Therapy with pulmonary 
arterial hypertension (PAH)-specific agents should be 
started when PoPHT is moderate to severe. Patients 
with a positive response should be encouraged to 
undergo liver transplant surgery. Bridging therapy with 
venous blood volume and pressure, pulmonary artery 
vasoconstriction and neurohumoral activation are 
responsible for the development of PoPHT in cirrhotic 
patients[9]. It has similar histopathological features 
as other types of PAH[10,11]. Obstruction of pulmonary 
arterial blood flow, proliferation of periarteriolar smooth 
muscle cells, vasoconstriction, increased endothelin 
concentrations, platelet aggregation/in situ thrombosis 
are characteristic findings in PoPHT and other forms of 
PAH[11-14]. The severity of liver disease did not correlate 
with the severity of PoPHT[15]. 
SYMPTOMS AND SIGNS
Symptoms of PoPHT may not be overt and may be 
attributed to underlying liver disease or associated 
conditions. Therefore, the recognition of PoPHT 
requires high clinical suspicion. Symptoms are similar 
to those in other forms of PAH. Dyspnea is the most 
common symptom in patients with PoPHT. Weakness, 
easy fatigue, edema, orthopnea, palpitation and 
chest pain on exertion are other common symptoms. 
Syncope may occur in patients with severe PoPHT. 
On physical examination, there may be jugular 
venous distension, a loud S2, left parasternal systolic 
murmur due to tricuspid regurgitation, peripheral 
edema, and ascites. 
Chest X-ray findings are non-diagnostic and may 
show cardiomegaly and dilation of main pulmonary 
arteries. Electrocardiographic findings include right 
bundle branch block, right axis deviation and precordial 
T wave inversions. Mild-moderate hypoxemia and 
hypocapnia are common in arterial blood gases 
analyses. 
ASSESSMENT 
TTDE is an accurate, reliable, and reproducible tool 
to estimate systolic PAP in the absence of pulmonary 
stenosis or right ventricular outflow tract obstruction[8]. 
It has high sensitivity as a screening test. Its non-
invasive nature makes it a recommended method 
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Table 1  Summary on assessment, grading and therapy for 
portopulmonary hypertension
TTDE in all patients prior to transplant surgery, systolic PAP ≥ 30 
mmHg
RHC in selected cases, confirmation and grading of PoPHT:
Mild PoPHT: mPAP > 25 mmHg, PVR > 240 dynes/s per cm-5, PCWP ≤ 
15 mmHg, allow LT
Moderate PoPHT: mPAP 35-45 mmHg, PVR > 240 dynes/s per cm-5, 
PCWP ≤ 15 mmHg if responder to vasodilator therapy, allow LT
Severe PoPHT: mPAP > 45 mmHg, PVR > 240 dynes/s per cm-5, PCWP 
≤ 15 mmHg, medical therapy
PoPHT: Portopulmonary hypertension; TTDE: Transthoracic Doppler 
echocardiography; PAP: Pulmonary artery pressure; RHC: Right 
heart catheterization; PVR: Pulmonary vascular resistance; LT: Liver 
transplantation.
these agents should be considered until the time of 
transplant surgery and continued during the peri and 
postoperative periods as needed. 
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INTRODUCTION
Patients with advanced liver disease display a variety 
of pulmonary abnormalities. Pulmonary vascular 
disorders - including portopulmonary hypertension 
(PoPHT) - are among the common complications 
of liver disease. Pulmonary hypertension in these 
patients is also defined as PoPHT when pulmonary 
arterial hypertension (PAH) is associated with portal 
hypertension[1-3]. Although it is commonly seen in 
cirrhotic patients, it may also occur in the absence of 
liver disease. The Nice World Pulmonary Hypertension 
Symposium classified PoPHT as one of the associated 
forms of PAH[4]. In this paper we review the literature 
about PoPHT in liver transplant candidates. 
DIAGNOSIS
The diagnosis of PoPHT requires the following 2 
conditions: (1) Elevated pulmonary arterial pressure 
(PAP) and other hemodynamic variables obtained 
by right heart catheterization (RHC). Mean PAP > 25 
mmHg, pulmonary capillary wedge pressure (PCWP) 
< 15 mmHg and pulmonary vascular resistance > 
240 dynes/s per cm-5; and (2) presence of portal 
hypertension (with or without liver disease). Documen-
tation of splenomegali, portosystemic shunts, thrombo-
cytopenia or varices - these are accepted as signs of 
portal hypertension. 
Assessment and staging severity of PoPHT based 
on transthoracic Doppler echocardiography (TTDE) and 
RHC are provided in Table 1[1].
EPIDEMIOLOGY AND 
PATHOPHYSIOLOGY
Although evidence varies widely, PoPHT is seen in 
as many as quarter of patients with advanced liver 
disease[5]. Krowka et al[6] demonstrated that 5% of 
patients with chronic liver disease have hemodynamic 
criteria for PoPHT. Data from a French PAH registry 
showed a prevalence of 9.4%[7]. A report from the 
multicenter United States-based REVEAL registry 
involving more than 3500 patients showed that 5% had 
PoPHT[8]. The exact pathogenesis of PoPHT is not well 
defined. Arterial hyperdynamic circulation, increased 
to screen for PoPHT in patients with cirrhosis[7]. Pul-
monary artery pressure should be carefully evaluated. 
For this purpose, the maximum tricuspid regurgitant 
flow velocity (v) should be obtained using continuous 
wave Doppler examination followed by systolic PAP 
calculations using the modified Bernoulli equation. 
[Systolic PAP (mmHg) = 4v2 + estimated mean right 
atrial pressure]. Patients with a systolic PAP value 
≥ 30 mmHg are usually diagnosed with PoPHT[16]. 
With this cutoff (30 mmHg), positive and negative 
predictive values of 59% and 100% respectively were 
reached[17]. 
TTDE also provides additional valuable information 
about the indirect signs of PAH such as right ventricular 
dilatation, right ventricular hypertrophy and abnormal 
septal motion[18]. TTDE has a pivotal role in the 
initial evaluation of PoPHT as recommended by both 
European and the American guidelines[19,20]. 
Because PoPHT has prognostic significance it 
is common belief that TTDE is mandatory in the 
evaluation of cirrhotic patients prior to liver transplant 
even when the patient is asymptomatic. 
However, the exact timing of RHC and systolic 
PAP cutoff values have yet to be identified. Different 
centers report varying approaches. A systolic PAP 
value > 50 mmHg via TTDE gave a sensitivity of 97% 
and a specificity of 77% via RHC[21]. This suggests 
that RHC should be considered when systolic PAP 
> 50 mmHg and in situations where systolic PAP is 
30-50 mmHg with other signs of PoPHT such as right 
ventricular dilation or dysfunction as well as signs of 
right ventricular failure. 
RHC is the gold standard method for the diagnosis 
of PoPHT[3,22]. Not only does it confirm PoPHT but it 
also provides additional data to exclude other causes 
of PAH in liver transplant candidates. By obtaining 
pulmonary vascular resistance (PVR), cardiac output, 
mean PAP and PCWP, the nature and severity of 
PoPHT can be highlighted (Table 1). For example, 
in cases of left heart disease, the cardiac output 
(CO) is reduced and PVR and PCWP are increased. 
In patients with PoPHT, CO and PCWP are low while 
PVR is elevated. In the hyperdynamic state the 
CO increases, PCWP is normal and PVR decreases. 
Because the treatment and prognosis of these clinical 
conditions are entirely different, their documentation is 
very important. Patients with elevated mean PAP but 
normal PVR (hyperdynamic state) benefit from liver 
transplantation. These patients should proceed to liver 
transplant surgery without further characterization 
and treatment. The trans-pulmonary gradient can 
be calculated as a mean PAP-PCWP. Values above 12 
mmHg have been shown to correlate with increased 
PVR[23,24]. 
PROGNOSIS AND OUTCOME
Without liver transplantation and medical therapy, 
cirrhotic patients with PoPHT have very poor pro-
gnosis[13,25,26]. Before the availability of PAH-specific 
therapies, the survival of patients with PoPHT is very 
poor[27]. Swanson et al[28] from the Mayo Clinic reported 
a 14% survival at 5 years in PoPHT patients without 
liver transplantation and PAH-specific therapies. 
Complications of advanced liver disease and right 
ventricular failure due to progressive elevation in PAP 
are responsible for poor survival rates. 
A study by Kia et al[29] demonstrated that ele-
vated PAP determined by TTDE was associated with 
increased mortality and morbidity following liver 
transplant surgery. Data from the Multicenter Liver 
Transplant Database demonstrated a mortality rate 
of 36% in patients with PoPHT undergoing liver 
transplantation[30]. The exact mechanism of how 
the risk increases in cirrhotic patients with PoPHT 
following liver transplant surgery is unclear. However, 
multisystemic involvement, pleural effusion, right-
sided heart failure, peri- and post-operative fluid shift, 
hypoxia and surgical trauma are among the possible 
mechanisms.
The REVEAL registry provides us with valuable infor-
mation regarding treatment and outcome of PoPHT[8]. 
Initiation of PAH-specific therapies were delayed in 
PoPHT vs idiopathic PAH. Baseline hemodynamics were 
better in PoPHT than those in idiopathic PAH; survival 
was worse in PoPHT. 
TREATMENT
Drug therapy
Calcium channel blockers are not advised in patients 
with PoPHT. As a consequence of mesenteric vaso-
dilation, they have the potential to worsen portal 
hypertension. Beta-blockers are not suggested 
because they may reduce exercise capacity. Warfarin 
anticoagulation is not recommended because of the 
risk of hemorrhage in cirrhotic patients. Diuretics are 
useful agents for symptomatic benefits in patients 
with volume overload and fluid retention. Both loop 
and potassium sparing diuretics can be used for this 
purpose. Oxygen therapy is recommended in hypoxic 
patients (PaO2 < 60 mmHg, O2 saturation < 90%). 
Data regarding the use of PAH-specific therapies 
are limited in patients with PoPHT. This is because 
most studies excluded patients with PoPHT. Table 2 
provides a short summary on the new PAH specific 
agents in use. However, these agents were used in 
small studies that enrolled a limited number of patients 
with PoPHT[31-35]. In general, these agents provided 
significant hemodynamic improvement. 
Liver transplantation
Innovation in surgical techniques, improvements in 
peri-operative care and developments in immune 
suppressant drugs have made organ transplantation 
the preferred therapy for patients with end stage 
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at 3-mo intervals because response to vasodilator 
therapy cannot be obtained with short-term use. Thus, 
the determination of acute responders during RHC is 
not recommended[37]. 
When PoPHT is severe it usually contraindicates 
liver transplantation[38,39]. Conversely, liver transplan-
tation is a therapeutic option in patients with PoPHT 
and advanced liver disease. A functioning liver 
graft decreases pulmonary artery pressure in these 
patients[28,36]. 
In a study by Starkel et al[5] PoPHT was identified 
in 38 of 145 patients (26%). It was mild in 82% of 
cases. The duration of mechanical ventilation and 
intensive care unit stay was similar between patients 
with and without PoPHT. One of the 5 patients who had 
severe PoPHT (mean PAP > 40 mmHg) died, but the 
remaining 4 patients were alive and in excellent clinical 
condition during the 3 years of follow up.
In the United States, transplant programs prioritize 
if the hemodynamics can be improved with PAH-
specific therapies and meet standardized MELD 
exception guidelines[40]. Goals of treatment for this 
approach are as follows: (1) Documentation of 
moderate to severe PoPHT by RHC (mean PAP ≥ 35 
mmHg, PCWP ≤ 15 mmHg, and PVR > 400 dynes/s 
per cm-5); (2) Improvement in hemodynamics with 
PAH-specific therapy (mean PAP < 35 mmHg, PVR < 
400 dynes/s per cm-5 and satisfactory right ventricular 
function on TTDE, as well as improvement in right 
ventricular dilation and function); and (3) MELD 
exception update every 3 mo.
The aim of this policy is to perform liver transplan-
tation before irreversible changes related to PoPHT 
occur. When liver transplantation is to be performed in 
patients with severe PoPHT demonstrating a positive 
response to vasodilator therapy, perioperative use 
of inhaled nitric oxide and intravenous epoprostenol 
should be considered. Adequate right ventricular 
function is very significant with regard to a successful 
transplant operation in patients with PoPHT. Prolonged 
PoPHT and progressively increasing PAP may predi-
spose subjects to right ventricular hypertrophy and 
eventually right ventricular dysfunction. In such cases 
an acute rise in cardiac output to more than 15 L/min 
during the reperfusion of the liver graft may precipitate 
acute right ventricular failure. Liver transplant surgery 
itself induces marked hemodynamic alterations that 
can adversely affect the peri-operative course in 
patients with pulmonary vascular disease. Acute right 
ventricular failure and right ventricular dysfunction 
may develop in patients with severe PoPHT that may 
be fatal. Therefore right ventricular function should 
also be evaluated during the peri- and post-operative 
periods. In case of right ventricular failure, milrinone 
can be used, and PAH specific agents should be 
continued following transplant surgery as necessary. 
Growing evidence suggests that unless severe 
and associated with right ventricular dysfunction, 
PoPHT should no longer be considered to be an 
organ failure. Liver transplantation is the best available 
therapeutic option for the treatment of patients with 
end stage liver disease. Advances in medical therapy 
for elevated PAP and liver transplant surgery, survival 
of patients with PoPHT and advanced liver disease are 
thus significantly improved[28]. Treatment strategies 
for PoPHT in cirrhotic patients are mainly based on 
recommendations for idiopathic PAH management 
and the treatment of underlying liver disease. Thus, 
by definition, a functioning transplanted liver graft 
emerges as a therapeutic option for PoPHT in such 
cases. As surgical techniques, hospital care, and PAH-
specific therapies have improved, the stabilization 
and improvement and even cure of PoPHT in cirrhotic 
patients is achievable with liver transplantation. In a 
previous study we determined that liver transplantation 
improves PoPHT[36]. 
Patients with mild PoPHT can safely undergo liver 
transplant surgery. In cases of moderate to severe 
PoPHT, the response to vasodilator therapy should be 
evaluated. When mean PAP is lowered to < 35 mmHg, 
patients benefit from liver transplant surgery and liver 
transplantation should be encouraged. 
Swanson et al[28] demonstrated that a combination 
of PAH-specific therapy and liver transplantation 
provided the best outcome vs those who did not 
receive any therapy and those who only received 
medical therapy. Survival at 5 years were 76%, 14% 
and 45%, respectively. These findings are valuable 
and clinically relevant. Therefore it is of great value 
to evaluate patients with moderate to severe PoPHT 
whether they respond or not. Unfortunately, there is 
no way to predict long-term response to vasodilator 
therapy. The evaluation of PAP should be repeated 
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Table 2  Pulmonary arterial hypertension-specific therapy: A 
summary of agents used
Entothelin receptor antagonists
   Agents used in PoPHT: bosentan, ambrisentan
   Mechanism of action: blockade of endothelin receptors
   Route of administration: oral
   Effects: vasodilation, decrease in PVR and portal pressure
   Adverse effects: hepatotoxicity 
PDE-5 inhibitors
   Agents used in PoPHT: sildenafil, tadalafil, vardenafil 
   Mechanism of action: inhibition of PDE-5 enzyme
   Route of administration: oral
   Effects: vasodilation, decrease in portal pressure
   Adverse effects: hypotension
Prostacyclins
   Agents used in PoPHT: epoprostenol, iloprost
   Mechanism of action: prostaglandin analogue, increase in cAMP
   Route of administration: epoprostenol IV, iloprost inhalation
   Effects: vasodilation, antiaggregation
   Adverse effects: flushing, headache, nausea, diarrhea. Problems 
   with IV epoprostenol use: cost, infection, catheter thrombosis, and 
   thrombocytopenia
PAH: Pulmonary arterial hypertension; PoPHT: Portopulmonary 
hypertension; PDE-5: Phosphodiesterase type 5 enzyme; PVR: Pulmonary 
vascular resistance; IV: Intravenous.
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absolute contraindication to liver transplantation. The 
current data indicate that PoPHT improves and even 
normalizes in some cases following successful liver 
transplantation[5,36,41]. Therefore, this suggests that 
liver transplantation should not be denied in all patients 
with severe PoPHT. When patients are in good clinical 
condition, young, and without severe right ventricular 
dysfunction or high pulmonary vascular resistance, 
improvements in PAP with vasodilator therapy liver 
transplantation should still be considered even when 
PoPHT is severe. 
Khaderi et al[42] reported the long-term follow 
up results of patients with severe PoPHT who 
underwent orthotopic liver transplantation. Of the 
488 liver transplant patients, 7 had severe PoPHT. 
All 7 of these patients received vasodilator therapy 
(6 patients IV epoprostenol, 1 oral sildenafil) and 
their mean PAP reduced to ≤ 35 mmHg. They also 
received IV or inhaled epoprostenol during the peri-
operative period. The survival rate was 85.7% after 
a median follow up of 7.8 years. Furthermore, all 
the surviving patients were in good functional status 
(NYHA Ⅰ or Ⅱ). Although the number of patients 
enrolled is small, the findings of this study are valuable 
and clinically relevant. This demonstrates that liver 
transplantation improves PoPHT even when severe. 
The authors concluded that moderate to severe PoPHT 
responsive to vasodilator therapy does well with liver 
transplantation, and such patients should be accepted 
as good candidates for transplant surgery.
CONCLUSION
Given the prognostic significance of PoPHT and the 
limited donor pool, a comprehensive preoperative 
cardio-pulmonary assessment is of paramount impor-
tance in cirrhotic patients prior to transplant surgery. 
A detailed Doppler echocardiographic examination 
must be the essential component of this evaluation. 
Pulmonary artery pressure should be calculated and 
right ventricular function should also be assessed. The 
RHC should be considered when PoPHT is moderate to 
severe. 
PAH-specific agents - either alone or in combination 
- are critical when deciding on liver transplant 
surgery in patients with moderate to severe PoPHT. 
Liver transplantation should be encouraged in cases 
displaying a positive response. Bridging therapy with 
specific PAH treatment agents should be considered 
until transplant surgery. This should be continued 
during the perioperative period and following surgery 
as needed. 
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